Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- Registration Number
- NCT00230386
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
This is a pilot study of 50 patients to establish whether there is a potential role for MRI perfusion in the detection of locally recurrent or persistent prostate carcinoma after previous treatment with radiotherapy. All subjects will be patients who have had localised prostate cancer treated with radiotherapy and have already agreed to undergo a biopsy of the prostate to look at local control within the prostate as part of their management. The objective of the study is to establish whether there is a relationship between recurrent or persistent disease within the prostate and increased perfusion on MRI at these sites.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
- Previously have had radical radiotherapy for localised prostate cancer
- Due to undergo routine post-treatment prostatic biopsies
- Suitable for MRI scan
- Adequate renal function
- No previous reaction to gadolinium
- Able to give informed consent
- No recent prostate biopsy within 6 weeks of enrolment
- Performance status (Eastern Cooperative Oncology Group [ECOG]) 0 or 1
Read More
Exclusion Criteria
- Not suitable for MRI scan
- Previous reaction to gadolinium
- Impaired renal function
- Inability to give informed consent
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To determine whether there may be a role for MRI perfusion in the detection of recurrent or persistent prostatic cancer after previous radiotherapy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Health Network Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada